Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

jj_2johnson_and_johnson

J&J and Genmab’s drug races to second line treatment approval

November 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …

News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …

News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016
Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …

News
janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

News
code

BenevolentAI announces licensing agreement with Janssen

November 8, 2016
Research and Development Janssen, Johnson & Johnson, artificial intelligence

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, …

News
janssen_latest_logo_on_sign

NICE knocks back Janssen rare disease drug

October 13, 2016
Medical Communications Janssen, NICE, imbruvica

NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …

News

NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund

August 18, 2016
Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica

NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …

News
janssen_latest_logo_on_sign_closer

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016
Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …

News

FDA issues warnings on Janssen, AstraZeneca diabetes drugs

June 15, 2016
Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana

The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …

News
janssen_latest_logo_on_sign_closer

Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study

June 14, 2016
Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica

Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …

News
janssen_latest_logo_on_sign

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

June 10, 2016
Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.  The company said …

News
lab

GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial

June 9, 2016
Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab

GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …

News
janssen_latest_logo_on_sign_closer

Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

June 6, 2016
Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.  The company …

News
janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016
Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024